{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:55Z","timestamp":1772165755354,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology and other clinics. 86 (82.7%) of 104 patients had systemic mastocytosis. Osteoporosis, disease-related complications, and secondary malignancies are important topics in this group. We know that indolent form has great survival. But smoldering or aggressive mastocytosis has a poor prognosis. CM and indolent SM have a significantly better prognosis compared to aggressive SM (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). We found that the presence of more than 25% of mast cells in the bone marrow, the presence of concomitant marrow dysplasia, and the presence of disease-related complications affect survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In addition to the WHO classification, the IPSM scoring system is indicative of the prognosis in this rare disease.\n                  <\/jats:p>","DOI":"10.1186\/s12885-022-10498-3","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:02:27Z","timestamp":1674576147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive mastocytosis data analysis from a single center"],"prefix":"10.1186","volume":"23","author":[{"given":"Tar\u0131k Onur","family":"Tiryaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0131d\u0131ka G\u00fclkan","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simge","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aynur Da\u011flar","family":"Aday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130pek Y\u00f6nal","family":"Hindilerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131","family":"Gelincik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Baykal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl\u00e7in","family":"Yegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130brahim \u00d6ner","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nesimi","family":"B\u00fcy\u00fckbabani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha","family":"Nal\u00e7ac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akif Selim","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"10498_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H, Kristensen T, M\u00f8ller M, Bindslev-Jensen C, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166:521\u20138. https:\/\/doi.org\/10.1111\/bjh.12916.","journal-title":"Br J Haematol"},{"key":"10498_CR2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","volume":"131","author":"JJ van Doormaal","year":"2013","unstructured":"van Doormaal JJ, Arends S, Brunekreeft KL, van der Wal VB, Sietsma J, van Voorst Vader PC, et al. Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol. 2013;131:1429\u201331.e1. https:\/\/doi.org\/10.1016\/j.jaci.2012.10.015.","journal-title":"J Allergy Clin Immunol"},{"key":"10498_CR3","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1016\/j.jaip.2020.05.005","volume":"8","author":"J Schwaab","year":"2020","unstructured":"Schwaab J, do OHN C, Naumann N, Jawhar M, Wei\u00df C, Metzgeroth G, et al. Importance of adequate diagnostic workup for correct diagnosis of advanced systemic Mastocytosis. J Allergy Clin Immunol Pract. 2020;8:3121\u20137.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.05.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"16","key":"10498_CR4","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.3390\/cancers14163942","volume":"14","author":"J Ungerstedt","year":"2022","unstructured":"Ungerstedt J, Ljung C, Klimkowska M, G\u00fclen T. Clinical outcomes of adults with systemic Mastocytosis: a 15-year multidisciplinary experience. Cancers (Basel). 2022;14(16):3942.","journal-title":"Cancers (Basel)"},{"key":"10498_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420\u20137. https:\/\/doi.org\/10.1182\/blood-2016-09-731893.","journal-title":"Blood."},{"key":"10498_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000504099","volume":"87","author":"R Leguit","year":"2020","unstructured":"Leguit R, Hebeda K, Kremer M, van der Walt J, Gianelli U, Tzankov A, et al. The Spectrum of aggressive Mastocytosis: a workshop report and literature review. Pathobiology. 2020;87:2\u201319. https:\/\/doi.org\/10.1159\/000504099.","journal-title":"Pathobiology."},{"key":"10498_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, M\u00f8ller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13:180\u20138. https:\/\/doi.org\/10.1016\/j.jmoldx.2010.10.004.","journal-title":"J Mol Diagn"},{"key":"10498_CR8","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/s2352-3026(19)30166-8","volume":"6","author":"WR Sperr","year":"2019","unstructured":"Sperr WR, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink JNG, Gorska A, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019;6:e638\u2013e49. https:\/\/doi.org\/10.1016\/s2352-3026(19)30166-8.","journal-title":"Lancet Haematol"},{"key":"10498_CR9","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","volume":"121","author":"J Gotlib","year":"2013","unstructured":"Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, et al. International working group-Myeloproliferative neoplasms research and treatment (IWG-MRT) & European competence network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013;121:2393\u2013401. https:\/\/doi.org\/10.1182\/blood-2012-09-458521.","journal-title":"Blood."},{"key":"10498_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","volume":"137","author":"I \u00c1lvarez-Twose","year":"2016","unstructured":"\u00c1lvarez-Twose I, Jara-Acevedo M, Morgado JM, Garc\u00eda-Montero A, S\u00e1nchez-Mu\u00f1oz L, Teod\u00f3sio C, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168\u201378.e1. https:\/\/doi.org\/10.1016\/j.jaci.2015.05.008.","journal-title":"J Allergy Clin Immunol"},{"key":"10498_CR11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood."},{"key":"10498_CR12","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","volume":"91","author":"L Escribano","year":"1998","unstructured":"Escribano L, Orfao A, D\u00edaz-Agustin B, Villarrubia J, Cerver\u00f3 C, L\u00f3pez A, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731\u20136.","journal-title":"Blood."},{"key":"10498_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaip.2018.09.024","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Oude Elberink JNG, Gorska A, Lange M, Zanotti R, van Anrooij B, et al. The data registry of the European competence network on Mastocytosis (ECNM): set up, projects, and perspectives. J Allergy Clin Immunol Pract. 2019;7:81\u20137. https:\/\/doi.org\/10.1016\/j.jaip.2018.09.024.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10498_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000048179","volume":"127","author":"F F\u00e9ger","year":"2002","unstructured":"F\u00e9ger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002;127:110\u20134. https:\/\/doi.org\/10.1159\/000048179.","journal-title":"Int Arch Allergy Immunol"},{"key":"10498_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000017978","volume":"197","author":"B Tebbe","year":"1998","unstructured":"Tebbe B, Stavropoulos PG, Krasagakis K, Orfanos CE. Cutaneous mastocytosis in adults. Evaluation of 14 patients with respect to systemic disease manifestations. Dermatology. 1998;197:101\u20138. https:\/\/doi.org\/10.1159\/000017978.","journal-title":"Dermatology."},{"key":"10498_CR16","doi-asserted-by":"publisher","first-page":"e12848","DOI":"10.1111\/dth.12848","volume":"32","author":"T Hinojosa","year":"2019","unstructured":"Hinojosa T, Lewis DJ, Vangipuram R, Safeer L, Mui UN, Haley C, et al. The efficacy of omalizumab in cutaneous Mastocytosis: a case series. Dermatol Ther. 2019;32:e12848. https:\/\/doi.org\/10.1111\/dth.12848.","journal-title":"Dermatol Ther"},{"key":"10498_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.5114\/ada.2018.77605","volume":"35","author":"J Czarny","year":"2018","unstructured":"Czarny J, Lange M, \u0141ugowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol Alergol. 2018;35:541\u20135. https:\/\/doi.org\/10.5114\/ada.2018.77605.","journal-title":"Postepy Dermatol Alergol"},{"key":"10498_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","volume":"124","author":"L Escribano","year":"2009","unstructured":"Escribano L, Alvarez-Twose I, S\u00e1nchez-Mu\u00f1oz L, Garcia-Montero A, N\u00fa\u00f1ez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124:514\u201321. https:\/\/doi.org\/10.1016\/j.jaci.2009.05.003.","journal-title":"J Allergy Clin Immunol"},{"key":"10498_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ajh.24382","volume":"91","author":"L Pieri","year":"2016","unstructured":"Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, et al. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. Am J Hematol. 2016;91:692\u20139. https:\/\/doi.org\/10.1002\/ajh.24382.","journal-title":"Am J Hematol"},{"key":"10498_CR20","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727\u201336. https:\/\/doi.org\/10.1182\/blood-2009-02-205237.","journal-title":"Blood."},{"key":"10498_CR21","doi-asserted-by":"publisher","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","volume":"9","author":"G Damaj","year":"2014","unstructured":"Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9:e85362. https:\/\/doi.org\/10.1371\/journal.pone.0085362.","journal-title":"PLoS One"},{"key":"10498_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1309\/ajcp1q0ysxeahnkk","volume":"140","author":"RC Johnson","year":"2013","unstructured":"Johnson RC, Savage NM, Chiang T, Gotlib JR, Cherry AM, Arber DA, et al. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013;140:525\u201335. https:\/\/doi.org\/10.1309\/ajcp1q0ysxeahnkk.","journal-title":"Am J Clin Pathol"},{"key":"10498_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41375-020-01073-5","volume":"35","author":"JM Capo-Chichi","year":"2021","unstructured":"Capo-Chichi JM, Kagotho E, Nayyar R, Zhao D, Minden M, Chang H. Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KIT(D816V) and FLT3-ITD. Leukemia. 2021;35:282\u20135. https:\/\/doi.org\/10.1038\/s41375-020-01073-5.","journal-title":"Leukemia."},{"key":"10498_CR24","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jaip.2017.02.008","volume":"5","author":"T G\u00fclen","year":"2017","unstructured":"G\u00fclen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic Mastocytosis. J Allergy Clin Immunol Pract. 2017;5:1248\u201355. https:\/\/doi.org\/10.1016\/j.jaip.2017.02.008.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10498_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/ajh.24490","volume":"91","author":"S Broesby-Olsen","year":"2016","unstructured":"Broesby-Olsen S, Farkas DK, Vestergaard H, Hermann AP, M\u00f8ller MB, Mortz CG, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol. 2016;91:1069\u201375. https:\/\/doi.org\/10.1002\/ajh.24490.","journal-title":"Am J Hematol"},{"key":"10498_CR26","doi-asserted-by":"crossref","unstructured":"Cem Akin, Valent Peter, Hartmann Karin, Alvarez-Twose Ivan, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5:e646.","DOI":"10.1097\/HS9.0000000000000646"},{"key":"10498_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","volume":"105","author":"Y Degbo\u00e9","year":"2017","unstructured":"Degbo\u00e9 Y, Eischen M, Nigon D, Apoil PA, Mailhol C, Tournier E, et al. Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone. 2017;105:219\u201325. https:\/\/doi.org\/10.1016\/j.bone.2017.09.005.","journal-title":"Bone."},{"key":"10498_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-019-03119-3","volume":"146","author":"P Riffel","year":"2020","unstructured":"Riffel P, Schwaab J, Lutz C, Naumann N, Metzgeroth G, Fabarius A, et al. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol. 2020;146:945\u201351. https:\/\/doi.org\/10.1007\/s00432-019-03119-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"10498_CR29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/modpathol.2010.224","volume":"24","author":"K Sotlar","year":"2011","unstructured":"Sotlar K, Cerny-Reiterer S, Petat-Dutter K, Hessel H, Berezowska S, M\u00fcllauer L, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol. 2011;24:585\u201395. https:\/\/doi.org\/10.1038\/modpathol.2010.224.","journal-title":"Mod Pathol"},{"key":"10498_CR30","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","volume":"22","author":"C Ustun","year":"2016","unstructured":"Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic Mastocytosis. Biol Blood Marrow Transplant. 2016;22:1348\u201356. https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.018.","journal-title":"Biol Blood Marrow Transplant"},{"key":"10498_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","volume":"80","author":"DS Avapritinib","year":"2020","unstructured":"Avapritinib DS. First approval. Drugs. 2020;80:433\u20139. https:\/\/doi.org\/10.1007\/s40265-020-01275-2.","journal-title":"Drugs."},{"key":"10498_CR32","doi-asserted-by":"publisher","unstructured":"Rapid responses to Avapritinib (BLU-285) in Mastocytosis. Cancer Discov. 2018;8:133. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2017-177.","DOI":"10.1158\/2159-8290.CD-NB2017-177"},{"key":"10498_CR33","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/all.14248","volume":"75","author":"J Trizuljak","year":"2020","unstructured":"Trizuljak J, Sperr WR, Nekvindov\u00e1 L, Elberink HO, Gleixner KV, Gorska A, et al. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy. 2020;75:1927\u201338. https:\/\/doi.org\/10.1111\/all.14248.","journal-title":"Allergy."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10498-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:02:31Z","timestamp":1674576151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10498-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10498"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10498-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1801037\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee (Istanbul University, Istanbul Faculty of Medicine Ethics Committee, Istanbul\/Turkey). The procedures followed were in accordance with the Declaration of Helsinki 1975, as revised in 2000, and patients had provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}